Ertugliflozin in Chronic Heart Failure
This study is looking at how two medications, ertugliflozin and metolazone, compare to a placebo (an inactive substance) in people with chronic heart failure. Researchers want to see how these treatments affect heart failure symptoms when added to your usual diuretic (water pill) therapy. You could be eligible if you have chronic heart failure, take a daily oral loop diuretic, have an eGFR (a measure of kidney function) of 20 mL/min/1.73 m2 or higher, and speak English. The study will measure changes in your body's fluid levels to understand how well these treatments work. The study is currently unclear on its recruitment status.
- Study design
- This is a randomized, placebo-controlled study involving about 60 participants. You would be randomly assigned to receive ertugliflozin, metolazone, or a placebo.
- What's involved
- You would receive treatment for six weeks. Researchers will measure changes in your plasma volume at 7 days and 6 weeks, and your natriuretic effect (how much salt your body gets rid of) at 1 day.
- Compensation
- Not stated in the trial record.
- Follow-up
- The study measures outcomes up to 6 weeks after starting treatment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Ertugliflozin in Chronic Heart Failure
At a glance
Conditions
NCT04438213
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Yale School of Medicine
New Haven, Connecticutno site contact published
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Jeffrey Testani, MD · PRINCIPAL_INVESTIGATOR · Yale University
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Change from baseline to day 7 of plasma volume by add-on to loop diuretic therapy7 days
The primary outcome of the chronic effects of add-on placebo, thiazide-like diuretic, or SGLT2 inhibitor is to determine the change in plasma volume from baseline to day 7
- Change from baseline to 6 weeks of plasma volume by add-on to loop diuretic therapy6 weeks
The primary outcome of the chronic effects of add-on placebo, thiazide-like diuretic, or SGLT2 inhibitor is to determine the change in plasma volume from baseline to 6 weeks
- Natriuretic effect of adjuvant to loop diuretic therapy1 day
The natriuretic effect of each arm with loop diuretic therapy will be measured by the urine sodium output and FeNa.